

**Radiosynthesis and biological evaluation of two  $^{18}\text{F}$ -labeled PET radioligands for  $\alpha$ -synuclein**

Yanbo Yu<sup>1</sup>, Lin Qiu<sup>1</sup>, Hao Jiang<sup>1</sup>, Dhruva Dhavale<sup>2</sup>, Paul Kotzbauer<sup>2</sup>, Joel S. Perlmutter<sup>2</sup>, Wai Kit Chia<sup>3</sup>, Robert Mach<sup>3</sup> and Zhude Tu<sup>1\*</sup>


<sup>1</sup>Departments of Radiology, <sup>2</sup> Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110

<sup>3</sup>Department of Radiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104,


# Parkinson disease and alpha-synuclein protein

- Parkinson's Disease (PD) is the second most common neurodegenerative disease
- The motor symptoms of PD are caused by degeneration of dopaminergic neurons in the substantia nigra, which is accompanied by Lewy bodies (LBs) and Lewy neuritis (LNs)
- $\alpha$ -Synuclein is the main component of Lewy bodies and Lewy neuritis, and plays an important function in the CNS by regulating synaptic vesicle recycling and synthesis, vesicular storage and release of neurotransmitter
- Accumulation of  $\alpha$ -synuclein aggregation may cause synaptic dysfunction and neuronal cell death
- $\alpha$ -synuclein is a pathological hallmark of Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA).
- A suitable PET radiotracer targeting  $\alpha$ -synuclein could be useful in early diagnosis of PD, disease progression, and assessment of the efficacy of disease-modifying therapies


# Radioligands for $\alpha$ -Synuclein




[<sup>11</sup>C]PIB



[<sup>18</sup>F]BF227




[<sup>125</sup>I]IDP-4




[<sup>11</sup>C]SIL5 R = <sup>11</sup>CH<sub>3</sub>

[<sup>125</sup>I]SIL23 R = (E)-CH<sub>2</sub>CHCH<sup>125</sup>I

[<sup>18</sup>F]SIL26 R = CH<sub>2</sub>CH<sub>2</sub><sup>18</sup>F




[<sup>18</sup>F]WC-58a




[<sup>11</sup>C]13 R = <sup>11</sup>CH<sub>3</sub>


[<sup>18</sup>F]14 R = CH<sub>2</sub>CH<sub>2</sub><sup>18</sup>F




[<sup>18</sup>F]28



[<sup>18</sup>F]BQ2




[<sup>11</sup>C] anle 253b




[<sup>11</sup>C]KY-2-15

- Radiotracer [<sup>18</sup>F]ACI-12589 was reported as PET radiotracer for imaging alpha-synuclein in the human brain by AC immune (<https://clinicaltrials.gov/ct2/show/results/NCT05067192>).
- Data suggested that [<sup>18</sup>F]ACI-12589 tracer binding in the brain is consistent with expected patterns of  $\alpha$ -synuclein pathology
- However, further evaluation of disease and target specificity, and potential PET signal retention in a-syn-positive PD/dementia are still needed.




# Design and synthesis strategy





# *In vivo* screening of each new compounds



Name	K <sub>i</sub> (nM), in a-syn fibrils v.s. [ <sup>3</sup> H]BF2846	max%inh_site9	K <sub>i</sub> (nM) in AD vs [ <sup>3</sup> H]PiB	max % Inh PiB
<b>TZ80-156</b>	14.95 ± 19.07	100	>1000	NA
<b>TZ83-41</b>	12.5 ± 40.81	60	362 ± 372	40




# Syntheses of precursors




Reaction and conditions: (a)  $\text{Pd}_2(\text{dba})_3$ , XantPhos,  $\text{Cs}_2\text{CO}_3$ , 1,4-dioxane, 110 °C; (b) 6 M HCl, MeOH, 70 °C; (c)  $\text{Boc}_2\text{O}$ , DMAP, RT; (d)  $\text{Cs}_2\text{CO}_3$ , MeOH, RT; (e) (E)-1,4-dibromobut-2-ene,  $\text{Cs}_2\text{CO}_3$ , acetone, RT.

# Radiosynthesis of [<sup>18</sup>F]TZ83-41 and [<sup>18</sup>F]TZ80-156



- Specific activity (SA): (> 37 GBq/μmol, at the end of synthesis (EOS)).
- Radiochemical and chemical purity > 98%


# PET study in the brain nonhuman primate



- The brain standardized uptake values (SUVs) for  $[^{18}\text{F}]\text{TZ83-41}$  and  $[^{18}\text{F}]\text{TZ80-156}$  reached a maximum ( $\sim 2.0$ ) at 6-7 min post tracer injection, followed by a favorable washout rate from the NHP brain.
- It suggests that both radioligands could cross the blood brain barrier,  $[^{18}\text{F}]\text{TZ80-156}$  may have defluorination *in vivo*.




# Tissue biodistribution in Sprague-Dawley rats



- [<sup>18</sup>F]TZ83-41 had a good brain uptake up to 0.71~0.24 %ID/gram from 5 to 120 min.
- For [<sup>18</sup>F]TZ80-156, the brain uptake dramatically decreased to 0.25 at 30 min, and 0.16 at 60 min. **Bone uptake increased** from 0.45 at 5 min to 2.18 at 30 min and 3.09 at 120 min.

# Radiometabolite analysis of NHP plasma samples



**Table 1.** HPLC metabolite analysis of NHP blood

	5 min	15 min	30 min	60 min	90 min	<i>In vitro</i> blood
<u>Radiometabolite</u>	7%	31%	41%	53%	62%	3%
$[^{18}\text{F}]\text{TZ83-41}$	93%	69%	59%	47%	38%	97%

- $[^{18}\text{F}]\text{TZ83-41}$  is relatively stable in NHP plasma and only one hydrophilic radiometabolite ( $t_R = 6.8$  min) is detected.

# Summary and future plan

- *In vitro* binding showed two compounds are potent and selective for alpha-synuclein.
- Two new F-18 labeled radioligands, [<sup>18</sup>F]TZ83-41 and [<sup>18</sup>F]TZ80-156 were radiosynthesized successfully.
- Both radiotracers could cross the blood brain barrier (SUV up to 2.0) and possess a good brain washout kinetics in the NHP.
- Radiometabolite analysis and rat biodistribution showed that [<sup>18</sup>F]TZ83-41 has no defluorination *in vivo*.
- Further evaluation will focus on [<sup>18</sup>F]TZ83-41 and determine if it be selected for translational clinic evaluation.

# Acknowledgements

- Washington University Cyclotron Facility
- Small Animal Preclinical Imaging Facility
- Nonhuman Primate PET Facility
- U of Penn, Dr. Robert Mach's group
- U of Pittsburg, Dr. Chester Mathis's group
  
- **Funding support:** National Institutes of Health (U19 NS110456)

# THANK YOU FOR YOUR ATTENTION!



# Addition information

- ID: SS14
- **Room:** S504ab
- **Session Date:** June 25, 2023
- **Session Time:** 12:30 PM - 1:45 PM  
**Session Type:** Scientific Session
- **Session Title:** Developments in Cardiovascular and Neurological Imaging
- **Abstract # /Title:** P1452 - *Radiosynthesis and biological evaluation of two 18F-labeled PET radioligands for  $\alpha$ -synuclein*  
**Presentation Time:** 1:05 PM - 1:15 PM (this includes 2 minutes for Q&A)
- Xuedan Wu
- Steven Liang
- Mausam Kalita
- Zhude Tu
- Divangana Lahad
- Allen Brooks
- Yadira Medina Guevara